Iwamura K
Third Department of Internal Medicine, School of Medicine, Tokai University, Japan.
Tokai J Exp Clin Med. 1986;11 Suppl:147-57.
In HBsAg carriers, the HBeAg has been regarded as an effectively infectious and progressive factor to B viral hepatitis. On the basis of the author's actual observations, it is clear that the clinical and pathological significance of HBeAg must be carefully reviewed. In the process, the problems to be focused upon are: 1) natural history of HBeAg and anti-HBe, 2) the clinical course before and after seroconversion from HBeAg to anti-HBe, and 3) the correlation between prognosis of B viral hepatitis and persistence of HBe-Ag and anti-HBe. On the basis of the author's observations, the author wishes to stress that to date we have only been able to observe an aspect of natural history of HBeAg and anti-HBe, and that the clinical and pathophysiological significance of HBeAg and anti-HBe remain still unexplained.
在乙肝表面抗原（HBsAg）携带者中，e抗原（HBeAg）一直被视为乙肝病毒感染和病情进展的一个有效因素。基于作者的实际观察，很明显，HBeAg的临床和病理意义必须得到仔细审视。在此过程中，需要关注的问题有：1）HBeAg和e抗体（anti-HBe）的自然史；2）从HBeAg血清学转换为anti-HBe之前和之后的临床病程；3）乙肝病毒感染的预后与HBeAg和anti-HBe持续存在之间的相关性。基于作者的观察，作者希望强调，迄今为止，我们仅能观察到HBeAg和anti-HBe自然史的一个方面，而HBeAg和anti-HBe的临床和病理生理意义仍未得到解释。
